# Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

> **NCT00150384** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 500 (—)

## Conditions studied

- Hypertension
- Dyslipidemia

## Interventions

- **DRUG:** Amlodipine/Atorvastatin

## Key facts

- **NCT ID:** NCT00150384
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 500 (—)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150384, "Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00150384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*